Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Fasenra

Drug and asset intelligence for Fasenra with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Sponsor company

RegulatoryJuly 16, 2026

The FDA has accepted a supplemental application for Fasenra (benralizumab) from AstraZeneca.

No catalysts indexed for this entity yet.

Topline Data

July 16, 2026 · N/A

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.